pharmaceuticals and stable liquid antibody compositions of il-17, process for reducing oxidation of secukinumab, use of an il-17 antibody and kit

摘要

The description relates to pharmaceuticals and stable liquid compositions of IL-17 antibodies and antigen binding fragments thereof, for example, ain457 (secukinumab), and to the manufacturing processes of these pharmaceuticals and compositions. The description also relates to the use of these pharmaceuticals and liquid compositions (e.g. as part of a kit having instructions for use) for the treatment of various il-17 mediated disorders (e.g. autoimmune disorders such as psoriasis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis).